ANDREWS, Steven W.;ARONOW, Sean;BLAKE, James F.;BRANDHUBER, Barbara J.;COLLIER, James;COOK, Adam;HAAS, Julia;JIANG, Yutong;KOLAKOWSKI, Gabrielle R.;MCFADDIN, Elizabeth A.;MCKENNEY, Megan L.;MCNULTY, Oren T.;METCALF, Andrew T.;MORENO, David A.;RAMANN, Ginelle A.;TANG, Tony P.;REN, Li;WALLS, Shane M.
发明人:
ANDREWS, Steven W.,ARONOW, Sean,BLAKE, James F.,BRANDHUBER, Barbara J.,COLLIER, James,COOK, Adam,HAAS, Julia,JIANG, Yutong,KOLAKOWSKI, Gabrielle R.,MCFADDIN, Elizabeth A.,MCKENNEY, Megan L.,MCNULTY, Oren T.,METCALF, Andrew T.,MORENO, David A.,RAMANN, Ginelle A.,TANG, Tony P.,REN, Li,WALLS, Shane M.
申请号:
WO2017US55993
公开号:
WO2018071454(A1)
申请日:
2017.10.10
申请国别(地区):
世界知识产权组织国际局
年份:
2018
代理人:
摘要:
Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.